GlassScriptPhysician profile
Joseph M Gray
NPI 1427672682
$5,070.42
in general payments reported to CMS, 2019-2025
35 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,937 · 2022: $1,260 · 2023: $336 · 2024: $202 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $698.00 | 2021-2025 | Fasenra, Breztri |
| Lilly USA, LLC | $641.54 | 2021-2024 | Mounjaro |
| Novo Nordisk INC | $412.92 | 2021-2023 | Wegovy |
| Amgen INC. | $386.38 | 2021-2022 | |
| Abbvie INC. | $372.32 | 2021-2022 | |
| Esperion Therapeutics, INC. | $364.93 | 2021 | |
| Alexion Pharmaceuticals, INC. | $243.70 | 2025 | |
| Astellas Pharma US INC | $222.75 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.48 | 2021-2022 | |
| Mannkind Corporation | $165.62 | 2021 | |
| Pfizer INC. | $134.57 | 2021 | |
| Amarin Pharma, INC. | $119.14 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $110.73 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $99.75 | 2021 | |
| Xeris Pharmaceuticals, INC. | $79.98 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $77.23 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $75.28 | 2021 | |
| Merck Sharp & Dohme LLC | $73.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.05 | 2022 | |
| Glaxosmithkline, LLC. | $60.61 | 2021 | |
| Neurocrine Biosciences, INC. | $52.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $51.18 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.11 | 2021 | |
| Eisai INC. | $44.62 | 2021 | |
| Shionogi INC | $38.60 | 2022 | |
| Sanofi-Aventis U.S. LLC | $34.30 | 2021-2022 | |
| Almatica Pharma LLC | $32.00 | 2021 | |
| Insulet Corporation | $31.67 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.38 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $29.73 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.08 | 2021 | |
| Genentech USA, INC. | $23.76 | 2021 | |
| Biogen, INC. | $18.85 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.65 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.